Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
Top Cited Papers
- 23 April 2020
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 382 (17), 1599-1607
- https://doi.org/10.1056/nejmoa1915103
Abstract
Recent guidelines recommend consideration of the use of oral edoxaban or rivaroxaban for the treatment of venous thromboembolism in patients with cancer. However, the benefit of these oral agents is limited by the increased risk of bleeding associated with their use.Funding Information
- Bristol-Myers Squibb
This publication has 18 references indexed in Scilit:
- Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)Journal of Clinical Oncology, 2018
- Edoxaban for the Treatment of Cancer-Associated Venous ThromboembolismNew England Journal of Medicine, 2018
- Epidemiology of first and recurrent venous thromboembolism in patients with active cancerThrombosis and Haemostasis, 2017
- The Clinical Course of Venous Thromboembolism May Differ According to Cancer SiteAmerican Journal Of Medicine, 2017
- Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active CancerJama-Journal Of The American Medical Association, 2015
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2013
- Apixaban for Extended Treatment of Venous ThromboembolismNew England Journal of Medicine, 2013
- Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with CancerNew England Journal of Medicine, 2003
- Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosisBlood, 2002
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999